Hologic Shares Surge 7.7% Amid Reports of New Acquisition Offer
PorAinvest
jueves, 18 de septiembre de 2025, 10:57 am ET1 min de lectura
HOLX--
The investment firms have re-engaged with Hologic’s board about a potential takeover and are currently conducting due diligence, according to Bloomberg. This renewed interest comes after the Financial Times reported in May that Blackstone and TPG had approached Hologic with an offer exceeding $16 billion, which was rejected at the time [1].
Despite the positive news, Hologic remains down 16.8% over the past 12 months. However, the company's stock has shown resilience, with several analysts maintaining a positive outlook. Hologic received an average "Moderate Buy" rating and a price target of $78.00, according to data from MarketBeat [2].
The company reported earnings of $1.08 per share for the last quarter, surpassing expectations, with revenue increasing by 1.2% year-over-year. Hologic's quarterly revenue was up 1.2% on a year-over-year basis, and the company has set its Q4 2025 guidance at 1.090-1.120 EPS. The FY 2025 guidance is at 4.230-4.260 EPS [2].
Institutional investors have also shown interest in Hologic. United Services Automobile Association bought a new stake in shares of Hologic during the first quarter, valued at approximately $347,000. Other hedge funds and institutional investors own 94.73% of the company's stock [3].
The renewed takeover interest and positive earnings reports suggest that Hologic may be on the path to recovery. However, any potential deal is still weeks away and there’s no certainty the talks will result in a transaction. Hologic and the investment firms have not publicly commented on the renewed takeover interest [1].
Hologic Inc. (NASDAQ:HOLX) shares jumped 7.69% to $68.20 on Wednesday amid reports of a renewed $16.7 billion takeover bid from Blackstone and TPG. The company has raised its revenue forecast for FY2025 to $4.08-$4.09 billion and expects Q4 revenues to hit $1.03-$1.04 billion.
Hologic Inc. (NASDAQ:HOLX) shares jumped 7.69% to $68.20 on Wednesday amid reports of a renewed $16.7 billion takeover bid from Blackstone and TPG. The medical device maker's stock has been an attractive acquisition target due to its recent stock performance challenges and the potential strategic value of its women's health products [1].The investment firms have re-engaged with Hologic’s board about a potential takeover and are currently conducting due diligence, according to Bloomberg. This renewed interest comes after the Financial Times reported in May that Blackstone and TPG had approached Hologic with an offer exceeding $16 billion, which was rejected at the time [1].
Despite the positive news, Hologic remains down 16.8% over the past 12 months. However, the company's stock has shown resilience, with several analysts maintaining a positive outlook. Hologic received an average "Moderate Buy" rating and a price target of $78.00, according to data from MarketBeat [2].
The company reported earnings of $1.08 per share for the last quarter, surpassing expectations, with revenue increasing by 1.2% year-over-year. Hologic's quarterly revenue was up 1.2% on a year-over-year basis, and the company has set its Q4 2025 guidance at 1.090-1.120 EPS. The FY 2025 guidance is at 4.230-4.260 EPS [2].
Institutional investors have also shown interest in Hologic. United Services Automobile Association bought a new stake in shares of Hologic during the first quarter, valued at approximately $347,000. Other hedge funds and institutional investors own 94.73% of the company's stock [3].
The renewed takeover interest and positive earnings reports suggest that Hologic may be on the path to recovery. However, any potential deal is still weeks away and there’s no certainty the talks will result in a transaction. Hologic and the investment firms have not publicly commented on the renewed takeover interest [1].
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios